See more : Iberdrola, S.A. (IBDRY) Income Statement Analysis – Financial Results
Complete financial analysis of ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShanXi C&Y Pharmaceutical Group Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Regions Financial Corporation (RN70.F) Income Statement Analysis – Financial Results
- Shield Therapeutics plc (SHIEF) Income Statement Analysis – Financial Results
- Samyang Tongsang Co., Ltd (002170.KS) Income Statement Analysis – Financial Results
- Regulus Resources Inc. (RGLSF) Income Statement Analysis – Financial Results
- Pruksa Holding Public Company Limited (PSH.BK) Income Statement Analysis – Financial Results
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cy-pharm.com
About ShanXi C&Y Pharmaceutical Group Co., Ltd.
ShanXi C&Y Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China, the United States, Hong Kong, and internationally. It offers products for pregnant women and babies; urinary system products; anti-infection products; traditional Chinese medicines; and dermatology products, as well as tea bags. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to Shanxi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Shanxi C&Y Pharmaceutical Group Co., LTD. was founded in 2005 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 799.31M | 829.00M | 930.37M | 848.07M | 1.13B | 1.14B | 938.93M | 746.08M | 683.93M | 653.66M | 513.51M | 361.50M | 310.78M | 319.55M | 243.62M | 203.67M | 203.67M |
| Cost of Revenue | 257.47M | 250.89M | 282.20M | 261.45M | 277.32M | 267.78M | 289.78M | 252.39M | 214.28M | 205.49M | 178.12M | 143.92M | 165.54M | 174.86M | 142.86M | 125.85M | 125.85M |
| Gross Profit | 541.83M | 578.10M | 648.17M | 586.62M | 854.48M | 868.72M | 649.15M | 493.69M | 469.65M | 448.17M | 335.39M | 217.58M | 145.24M | 144.69M | 100.76M | 77.81M | 77.81M |
| Gross Profit Ratio | 67.79% | 69.74% | 69.67% | 69.17% | 75.50% | 76.44% | 69.14% | 66.17% | 68.67% | 68.56% | 65.31% | 60.19% | 46.73% | 45.28% | 41.36% | 38.21% | 38.21% |
| Research & Development | 49.97M | 54.52M | 57.12M | 72.39M | 48.95M | 53.54M | 43.44M | 33.79M | 31.42M | 25.61M | 20.19M | 16.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.14M | 33.38M | 32.01M | 32.96M | 28.80M | 36.32M | 36.69M | 32.16M | 30.14M | 33.34M | 26.49M | 26.90M | 48.85M | 49.43M | 29.64M | 27.63M | 27.63M |
| Selling & Marketing | 261.75M | 417.58M | 479.02M | 556.21M | 693.45M | 624.56M | 429.16M | 283.48M | 269.50M | 255.72M | 188.75M | 105.68M | 48.78M | 39.74M | 26.56M | 29.24M | 29.24M |
| SG&A | 453.01M | 450.96M | 511.03M | 589.17M | 722.25M | 660.88M | 465.85M | 315.64M | 299.64M | 289.06M | 215.24M | 132.58M | 97.64M | 89.18M | 56.20M | 56.88M | 56.88M |
| Other Expenses | -3.77M | 25.07M | 14.09M | 16.72M | 43.01M | 29.58M | 12.46M | 21.36M | 7.72M | 9.62M | 1.60M | 15.29M | 1.65M | 14.19M | 7.18M | 8.28M | 4.24M |
| Operating Expenses | 501.68M | 590.06M | 653.30M | 752.05M | 861.04M | 817.84M | 602.98M | 447.00M | 416.24M | 390.08M | 286.34M | 192.28M | 100.69M | 91.79M | 58.03M | 58.51M | 58.51M |
| Cost & Expenses | 758.89M | 840.96M | 935.50M | 1.01B | 1.14B | 1.09B | 892.76M | 699.39M | 630.52M | 595.57M | 464.46M | 336.20M | 266.23M | 266.65M | 200.89M | 184.36M | 184.36M |
| Interest Income | 3.74M | 2.55M | 2.10M | 1.50M | 1.41M | 776.25K | 3.17M | 1.85M | 1.04M | 1.29M | 3.78M | 9.30M | 3.66M | 496.15K | 50.43K | 41.46K | -0.03 |
| Interest Expense | 33.29M | 46.06M | 49.17M | 54.68M | 18.12M | 13.60M | 15.42M | 14.15M | 9.15M | 6.53M | 4.11M | 5.55M | 4.04M | 4.87M | 5.80M | 4.06M | 4.04M |
| Depreciation & Amortization | 59.38M | 65.53M | 64.72M | 65.68M | 53.24M | 57.32M | 51.13M | 48.54M | 42.76M | 36.76M | 25.57M | 23.27M | 14.92M | 13.07M | 12.31M | 11.23M | 6.47M |
| EBITDA | 127.06M | 25.13M | 40.52M | -177.15M | 57.72M | 88.94M | 112.55M | 108.51M | 90.26M | 104.27M | 72.42M | 67.43M | 61.14M | 69.48M | 56.48M | 27.77M | 20.57M |
| EBITDA Ratio | 15.90% | 9.35% | 9.83% | -9.79% | 9.78% | 11.80% | 11.37% | 17.70% | 15.63% | 16.60% | 15.66% | 20.24% | 20.70% | 23.85% | 23.19% | 17.09% | 10.10% |
| Operating Income | 40.15M | -115.09M | -79.57M | -315.11M | -41.12M | -14.80M | 28.82M | 23.71M | 30.87M | 51.65M | 41.24M | 25.11M | 40.96M | 47.99M | 38.08M | 14.10M | 14.10M |
| Operating Income Ratio | 5.02% | -13.88% | -8.55% | -37.16% | -3.63% | -1.30% | 3.07% | 3.18% | 4.51% | 7.90% | 8.03% | 6.95% | 13.18% | 15.02% | 15.63% | 6.92% | 6.92% |
| Total Other Income/Expenses | 15.12M | -66.38M | -37.31M | -100.06M | 43.01M | -28.51M | 12.46M | 2.35M | -8.38M | 8.57M | 1.50M | 13.49M | 1.22M | 9.77M | 1.29M | 4.15M | 4.15M |
| Income Before Tax | 55.28M | -90.02M | -65.48M | -298.39M | 1.89M | 14.77M | 41.27M | 44.26M | 38.34M | 60.22M | 42.74M | 38.60M | 42.18M | 57.76M | 39.36M | 18.25M | 18.25M |
| Income Before Tax Ratio | 6.92% | -10.86% | -7.04% | -35.18% | 0.17% | 1.30% | 4.40% | 5.93% | 5.61% | 9.21% | 8.32% | 10.68% | 13.57% | 18.07% | 16.16% | 8.96% | 8.96% |
| Income Tax Expense | 6.55M | 7.97M | 9.07M | -17.82M | 3.67M | 5.00M | 10.38M | 6.70M | 9.29M | 4.33M | 7.66M | 5.57M | 6.84M | 9.77M | 10.46M | 5.21M | 5.21M |
| Net Income | 25.20M | -118.57M | -91.44M | -262.37M | 5.30M | 7.24M | 21.67M | 30.15M | 22.90M | 41.00M | 27.11M | 25.80M | 35.34M | 47.98M | 28.90M | 13.04M | 13.04M |
| Net Income Ratio | 3.15% | -14.30% | -9.83% | -30.94% | 0.47% | 0.64% | 2.31% | 4.04% | 3.35% | 6.27% | 5.28% | 7.14% | 11.37% | 15.02% | 11.86% | 6.40% | 6.40% |
| EPS | 0.10 | -0.50 | -0.40 | -1.23 | 0.03 | 0.03 | 0.10 | 0.14 | 0.14 | 0.26 | 0.14 | 0.13 | 0.22 | 0.33 | 0.20 | 0.10 | 0.10 |
| EPS Diluted | 0.10 | -0.50 | -0.40 | -1.23 | 0.03 | 0.03 | 0.10 | 0.14 | 0.14 | 0.26 | 0.14 | 0.13 | 0.22 | 0.33 | 0.20 | 0.10 | 0.10 |
| Weighted Avg Shares Out | 241.62M | 237.07M | 227.97M | 213.22M | 208.31M | 208.08M | 208.31M | 208.31M | 164.87M | 160.56M | 192.70M | 195.54M | 159.05M | 143.95M | 143.51M | 134.07M | 134.07M |
| Weighted Avg Shares Out (Dil) | 241.62M | 237.07M | 227.97M | 213.22M | 208.31M | 208.08M | 209.00M | 215.34M | 164.87M | 160.56M | 192.70M | 195.54M | 159.05M | 143.95M | 143.51M | 134.07M | 134.07M |
Source: https://incomestatements.info
Category: Stock Reports